# Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis

> **NCT03232073** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 877 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ponesimod

## Key facts

- **NCT ID:** NCT03232073
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-05
- **Primary completion:** 2024-01-16
- **Final completion:** 2024-01-16
- **Target enrollment:** 877 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232073, "Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03232073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*